Medical device sales are up in the U.S., but major players like J&J are facing market headwinds due to the VBP program in China.
4 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medical device sales are up in the U.S., but major players like J&J are facing market headwinds due to the VBP program in China.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- MedTech is identified as a soft spot in J&J case.Sub-event
J&J and competitors are navigating market growth while dealing with specific competitive pressures from China.1 source
Keep exploring
The entities involved
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Medtech
medical education facility founded in 2004 in Indianapolis, U.S
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ZacksJ&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue? Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vi
- Unknown outlet
- Unknown outlet
- Unknown outlet